Unlike traditional pain management, ReActiv8 therapy uniquely addresses chronic low back pain by restoring neuromuscular control and functional spine stability. In this episode, Dr. Chris Gilligan, MD, MBA, Executive Medical Director, Mass General Brigham Global Advisory, Senior Medical Director of Periprocedural Services, Director of Brigham and Women’s Spine Service Line, Chief - Division of Pain Medicine, Brigham and Women’s Hospital, discusses the groundbreaking five-year data on ReActiv8 therapy for chronic low back pain, offering insights into this transformative approach and its impact on patients' lives. Chris delves into the significant findings from his research, shedding light on the ReActiv8 therapy's effectiveness in addressing chronic low back pain and improving patients' quality of life. He provides an in-depth overview of the research, covering the methodology, patient demographics, and the remarkable outcomes achieved over the five-year study period. Dr. Gilligan also addresses the implications of the findings for payers, providers, and patients, offering a holistic perspective on the therapy's clinical and economic significance. Join Chris and Saul as they uncover the remarkable impact of this novel therapy and explore its broader implications for patients, physicians, and payers in the healthcare ecosystem. Resources:  Watch this amazing interview here. Connect with and follow Chris Gilligan on LinkedIn here. Learn more about ReActiv8-B Trial 3-Year Patient Outcomes Data here. Listen to Dr. Chris’s previous interview. Visit the Mainstay website here.